2023-08-02 07:07:50 ET
- Editas Medicine press release ( NASDAQ: EDIT ): Q2 GAAP EPS of -$0.56 beats by $0.21 .
- Revenue of $2.89M (-54.6% Y/Y) misses by $1.5M .
- Cash, cash equivalents, and marketable securities as of June 30, 2023, were $480.0 million compared to $401.8 million as of March 31, 2023. The company expects existing cash, cash equivalents and marketable securities to fund operating expenses and capital expenditures into the third quarter of 2025.
For further details see:
Editas Medicine GAAP EPS of -$0.56 beats by $0.21, revenue of $2.89M misses by $1.5M